...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree .. the word "1%" did not show up in the original PR - but it is about the same conference.
Chart is still looking like downward bias for couple more days before it is ready to go upward.
Cheers.
Yes ... that is why I remarked why did HDVY decide to combine the 2 news together ... the old news about MDB conference and the "new" news of a brand new patent.
Nah .. this is old news .. dated 2/17
Please see this link that "dollardaze" posted...
It has this blurb in it ...
"The Bright Lights Conference will showcase the untold IP stories of 50 public companies ranking in the 90th percentile for technology leadership from over 1,600 small cap companies with U.S. patents granted, as rated by PatentVest, MDB's proprietary IP business intelligence database".
The 1st part of the news is old news ... but the 2nd part is new - the one about a new patent.
Odd that they decided to put the two together.
Health Discovery Corporation Placed in the Top 1% of the "Best and Brightest" Companies by MDB Capital for its Game-Changing Technology
Last update: 2/26/2010 1:45:00 PM
HDC Receives Notice of Issuance from the United States Patent and Trademark Office for New U.S. Patent No. 7,676,442
SAVANNAH, Ga., Feb 26, 2010 (BUSINESS WIRE) -- Health Discovery Corporation (HDVY) announced today it has been selected by MDB Capital Group as one of its Top 50 "Best and Brightest" companies that will present at the invitation-only, 1st Annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property.
"Health Discovery Corporation was selected to present on the basis of ranking in the 90th percentile for IP leadership from over 1,600 small cap companies with U.S. patents granted, as rated by PatentVest, MDB Capital Group's proprietary IP intelligence platform," said Chris Marlett, Co-Founder, Chairman and CEO of MDB Capital Group.
"Health Discovery Corporation currently enjoys an impressive Tech Score of 3.93 placing the company in the Top 1% of 1,600 companies evaluated based on this metric," said Mr. Marlett.
"The primary selection metric used for Bright Lights is PatentVest's Tech Score, a proprietary measure of the industry impact of a company's patents based upon the analysis of patent citations relative to its peer group of patents," said Mr. Marlett. "We have found PatentVest Tech Score to be correlated to business performance, and therefore predictive of risk-adjusted returns, over the intermediate and longer-term." A related white paper is available from MDB Capital Group.
The conference will be held May 10-12, 2010, in San Francisco. The Company has accepted the invitation.
The Bright Lights Conference will be the first-ever public company conference of its kind -- a conference where small cap companies are chosen to present on the basis of their (often hidden) Intellectual Property value and potential for market-changing innovation. Institutional investors from several countries, as well as IP thought leaders, will be in attendance for the first public company conference to focus exclusively on selected companies with disruptive and market changing Intellectual property.
"MDB Capital Group should be commended for their ground-breaking methodology in analyzing the value of public companies' intellectual property," said Stephen D. Barnhill, Chairman and CEO, of Health Discovery Corporation. "The work done by MDB Capital validates our franchise and our pioneering leadership in the field of Support Vector Machines technology," said Dr. Barnhill. "We gladly accepted the invitation to present at this upcoming conference," said Dr. Barnhill.
HDC Granted New Patent
Health Discovery Corporation also announced that it received notification from the U.S. Patent and Trademark Office that its application entitled "Kernels and Kernel Methods for Spectral Data," will issue as Patent No. 7,676,442 on March 9, 2010. This new patent covers the use of SVMs in conjunction with a proprietary pre-processing technique to greatly improve analysis of data obtained using mass spectrometry. Mass spectrometry is widely used for chemical and biological testing and is particularly applicable to protein analysis for biomarker discovery.
Protein mass spectrometry data combined with SVMs was used by Vermillion, Inc. (Other OTCBB: VRMLQ.PK) in discovery of the genes in its OVA1 ovarian cancer test, which is expected to be brought to market by Quest Diagnostics, Incorporated (DGX) in March 2010.
A continuation application based on this new patent has been filed to expand Health Discovery Corporation's coverage of the use of SVMs for analysis of many other types of spectral data. Analysis of spectral data is required in virtually any technology in which a signal is detected, including communications, optics, intelligence, aerospace, defense, regulatory monitoring, including food and water safety testing, medical diagnostics, and consumer electronics.
HDC's Patent Portfolio
With the issuance of the new patent described above, HDC now holds exclusive rights to a total of 42 issued U.S. and foreign patents and 32 pending patents. HDC has a total of 74 patents pending and issued. Importantly, the earliest expiration of any of the HDC patents is May 2019, with most of the patents having terms that will provide additional protection of 5 or more years beyond that date.
New to this board ... I have been accumulating this stock yesterday and today ... had to buy at ask .185 because of the low volume.
Thank you all for the well documented research on this company in this board.
Looks like there is more chance of an upside than further downward bias. If it continues to dip, I will add more.
Cheers.
Interesting that they are adding someone with a Computer Science background ("expert in data mining and machine learning") - looks like they want to push / extend their SVM's role further!
That is good news. Looks like the company is taking the right steps and maintaining momentum. The PPS does not yet reflect that... but I am sure it will in a short while.
Cheers
Yes ... look at it this way, they get to use both of their resources - Hanbury as an advisor and link to new Lab network. And Graham for his experience in the small to mid market.
No harm done!
I view it as a plus.
Looks like Hanbury had personal reasons (relocation) as stated in the PR.
Health Discovery Corporation Announces Changes in Board of Directors
Press Release Source: Health Discovery Corporation On Wednesday February 24, 2010, 7:10 pm EST
SAVANNAH, Ga.--(BUSINESS WIRE)--Health Discovery Corporation (OTCBB: HDVY - News) (“HDC”) is pleased to announce that D. Paul Graham, Chief Executive Officer of Graham Capital Partners, LLC, has joined the Board of Directors effective immediately.
“To be able to attract someone of Paul Graham’s background and experience to join our Board of Directors is a real coup,” said Dr. Barnhill. “We’re delighted to have Paul’s quarter century of corporate governance, management experience and financial acumen at the service of the board on behalf of the shareholders,” said Dr. Barnhill.
“I am proud to join the board of Health Discovery Corporation. I look forward to working with the Board of Directors to advance the robust technology platform and exceptional pipeline of products that the Company has to offer,” said Mr. Graham.
Mr. Graham has had for over 24 years a passion and focus on mergers and acquisitions (M&A) and leadership excellence within the small-to-middle markets.
In 1997, after a successful 12-year career with one of Canada’s premier transportation companies, Mr. Graham opened offices in Toronto, Canada to bring M&A expertise and value to an underserviced sector of the small-to-middle market. In 2002, he added offices in Atlanta, Georgia, and in 2005 opened offices in Savannah, Georgia.
Graham Capital Partners, LLC provides investment banking and business advisory services to the small-to-middle markets for companies achieving revenues between $10 million and $100 million. He has been involved in acquisitions, divestitures, and financings totaling over $200 million in transaction value in North America. Mr. Graham leads Graham Capital Partners in M&A and advisory mandates in North America, Europe and North Africa.
Mr. Graham was educated at Lakehead University and York University in the disciplines of accounting and finance. Mr. Graham serves in an advisory capacity and as a director for a number of privately held corporations and is a member of the Atlanta chapter of Association for Corporate Growth.
Mr. Graham replaces Michael Hanbury, Ph.D., who has resigned from the Board of Directors due to a cross country family relocation and the acceptance of new senior executive responsibilities with Spectrum Laboratory Network, Greensboro, North Carolina. Spectrum Laboratory Network, is a full-service regional medical laboratory providing laboratory services to over 7,000 physicians, 10 hospitals, nursing homes, home health, clinics, urgent care facilities, business and industries.
Spectrum Laboratory Network was purchased for $230 million in December 2009, by Welsh, Carson, Anderson & Stowe, New York, NY, one of the largest and most successful private equity investment firms in the United States with an investment focus exclusively in healthcare and information/business services.
In January 2010, Carilion Labs, based in Roanoke, Va., entered into an agreement to merge with Spectrum Laboratory Network to form a major laboratory company offering comprehensive clinical, anatomic pathology and esoteric testing services. The merger will create a new and stronger regional hospital laboratory company, serving 37 hospitals and 14,000 physicians in eight states, with more than 2,600 employees and annual revenues above $300 million.
Dr. Hanbury will continue to assist Health Discovery Corporation as an unpaid advisor.
“I have relied on Dr. Hanbury’s insights, judgment and wise counsel for many years,” said Stephen D. Barnhill, M.D., Chairman and CEO, Health Discovery Corporation. “While we will miss Mike Hanbury’s presence on the Board, we are delighted that he remains as a valued advisor and collaborator,” said Dr. Barnhill.
Health Discovery Corporation's Executives to Present at "Personalized Medicine Partnerships" Conference This Morning
Last update: 2/24/2010 9:00:04 AM
SAVANNAH, Ga., Feb 24, 2010 (BUSINESS WIRE) -- Health Discovery Corporation (HDVY) ("HDC"), announced that two members of its senior management team will be speaking at the "Personalized Medicine Partnerships" conference taking place today in Philadelphia, PA. The conference is sponsored by Arrowhead Conferences, a business-to-business conference group based in Redlands, Calif.
Stephen D. Barnhill, M.D., Chairman and CEO, and John A. Norris, J.D., M.B.A., COO, of Health Discovery Corporation, will make a presentation describing the value of partnerships in furtherance of personalized medicine.
The Company has developed strong relationships with leading companies such as Quest Diagnostics Incorporated, and Abbott Laboratories to commercialize HDC's non-invasive, four-gene test for clinically-significant prostate cancer, among other initiatives.
Other presenters include representatives from Pfizer, AstraZeneca, Merck, J&J, Medco, Roche, PriceWaterhouseCoopers, LabCorp, Abbott, FDA, NCI, The European Commission, and The National Human Genome Institute.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology.
SVM Capital announces successful risk-adjusted, 14-month performance
Last update: 2/23/2010 10:53:02 AM
SAVANNAH, Ga., Feb 23, 2010 (BUSINESS WIRE) -- SVM Capital, LLC, announced today is making substantial progress in using Health Discovery Corporation's (HDVY) sophisticated pattern recognition technology (Support Vector Machines ("SVM")) for predicting the movements of the financial markets.
In November 2008 SVM Capital began live trading with its first model utilizing SVM technology. Trading a composite of the four major stock indices (S&P 500, Dow Jones 30 Industrials, the Nasdaq 100 and the Russell 2000), the broad market experienced a four-month decline of 23% through the end of February 2009. Beginning in March 2009, the broad markets rallied through December 2009.
During the four-month period (November 2008-February 2009) when the markets and the four indices were down 23% in the value, SVM Capital declined only 7.6%, outperforming the market by 15.4%. The SVM algorithm correctly predicted market downturns, which prompted SVM Capital to either hedge its risk or increase its cash position.
During the subsequent 10-month market rally in 2009, the composite indices made an impressive 55% gain. Meanwhile, SVM Capital gained 26%. For the entire 14-month period (November 2008-December 2009, inclusive) the composite indices gained 19%, while SVM Capital gained 16%, with much less risk.
"It's worth noting that while the four composite indices outperformed SVM Capital by 3% during the 14-month period, SVM Capital's gain of 16% was achieved with far less risk," said Mark A. Moore, Ph.D., Chairman, SVM Capital, LLC.
"We are pleased with these risk-adjusted results and lower risk is very important to today's investors," said Dr. Moore.
New Improvements to Trading Model Underway
SVM Capital continues to incorporate additional equity markets data in order to improve the initial trading model. A more robust model is expected to be trading live in the near future. This new model takes advantage of the addition of information to our data base and demonstrates again the capacity of SVM to deliver improved results while adding information. The new model has also demonstrated the capacity to perform well during periods of very strong market rallies such as we have seen in 2009. For the period of live trading from November 2008 to December 2009, the new model outperformed the composite four indices by a small margin. The composite of the four indices was up a total of 19% while our new SVM model was up over 20%, with lower risk. Again, the new SVM model outperformed the indices with lower risk.
"SVM Capital represents an excellent non-healthcare opportunity for Health Discovery Corporation to generate new revenue," said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. "We are impressed and pleased with Dr. Moore's progress to date," said Dr. Barnhill. As a part-owner, Health Discovery Corporation will receive revenue through a revenue sharing arrangement with SVM Capital.
About Health Discovery Corporation
Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology.
About SVM Capital, LLC
SVM Capital, LLC is a joint venture between Health Discovery Corporation and Atlantic-Alpha Strategies (Atlantic-Alpha). Atlantic Alpha was founded in 2006 to manage a fully-hedged equity arbitrage fund based on Dr. Mark Moore's proprietary pairs trading program. This in turn is the culmination of his particular expertise in developing specialized logic structures for value decisions in financial markets. He was a General Partner (1988-1992) of Millennium Partners Hedge Fund, an $11 billion global hedge fund. Dr. Moore's career has been focused on quantitative approaches for a variety of investment vehicles in the options, commodities, equities and debt markets. For more information contact Hayes Miller, CEO at fhmiller@atlantic-alpha.com.
Yes - I concur with you. HDVY has chosen their words very well and responded appropriately.
imho - HDVY did what it has to do - defend for itself. Some companies keep quiet - others do not.
It is a "Damn if you do, Damned if you don't". Can't please everybody. But the company has to stand up for what it does!
Some folks will question why isn't the company responding to these false statements. While others question if it does!
HDVY also is in a bind based on their contractual agreements with Quest, Abbott.
Chart for HDVY tells me that that we are in a downward bias (not much!) for next couple of days. Overall market sentiment tells me that we are setting up for a run (in the large cap equities).
Cheers.
Way to go HDVY ... !
Health Discovery Corporation Responds to Tabloid "News"
SAVANNAH, Ga., Feb 22, 2010 (BUSINESS WIRE) -- Health Discovery Corporation (HDVY) would like to respond to a tabloid story that appeared this past week about the Company that contained a number of untruths. It is worth noting that it appears that Health Discovery Corporation is caught in ongoing crossfire between two competing stock market news services, one that recently issued an independent, positive report on the Company that was, in turn, followed by the tabloid story last week.
The Company points out the following:
-- The Company takes very seriously its contractual obligations, including confidentiality provisions. As a result, the Company is required under contract law to limit the amount of information it can provide the public, including journalists. We make no apologies for adhering to our contractual obligations.
-- The Company stands by the superior sensitivity and specificity of our new, non-invasive, four-gene prostate cancer test published in the peer-reviewed publication, UroToday, in August, 2009. The Company stands by its public disclosures related to this test and is pleased with its continued progress.
Here are some independent commentaries on the PSA:
Dr. Otis Brawley, the chief medical officer of the American Cancer Society, and quoted in last week's tabloid attack on Health Discovery Corporation, had this to say about the PSA: "The PSA test is about 50 times more likely to ruin your life than it is to save your life."
The New England Journal of Medicine published in March 2009 the results of the largest prostate cancer studies in the U.S. and Europe, which said: "We now know that prostate-cancer screening (PSA) provided no reduction in the death rates at 7 years and that no indication of a benefit appeared with 67% of the subjects having completed 10 years of follow-up."
"The rate of overdiagnosis of prostate cancer has been estimated to be as high as 50% in the (PSA) screening group... Overdiagnosis and overtreatment are probably the most important adverse effects of prostate-cancer screening and are vastly more common than in screening for breast, colorectal, or cervical cancer."
New York Times reporter, Tara Parker Pope, wrote about these two major studies on prostate cancer and the merits of the PSA: "...[the PSA] saves few if any lives, while exposing patients to aggressive and unnecessary treatments that can leave them impotent and incontinent."
Wall Street Journal writer Melinda Beck wrote about these two studies: "But two big studies in the New England Journal of Medicine just found that screening for PSA - prostate specific antigen - doesn't save many lives."
Dr. Bernadine Healy, former head of the National Institutes of Health, wrote in U.S. News & World Report last year about the value of the PSA test, "...to save one life, more than 1,000 men would have to be screened and 48 treated. That's a lot of screening, expense, and potentially unnecessary treatment."
According to oncologist Jonathan Simons, president of the Prostate Cancer Foundation, "We've got potentially game-changing biomarkers that could get us out of the dilemma we are in with the PSA."
Health Discovery Corporation agrees with the outcomes of the two largest, published studies on the PSA and prostate cancer that there is an urgent need to replace the PSA and with Dr.
Brawley's assessment of the serious risks that the PSA test will ruin your life, with Dr. Healy's observation about unnecessary expense and treatment, and with Dr. Simons' keen observation about the value of new game-changing biomarkers.
-- The nature of scientific discovery involves, among other things, hundreds of confidential conversations among Stephen Barnhill, M.D., Chairman and CEO of Health Discovery Corporation, our scientists and the scientists and business development professionals employed by our partners. Last week's tabloid story simply does not have access to such conversations.
-- The story stated that any new prostate cancer test "will need to be reviewed and approved by the FDA." This is patently untrue, since lab developed tests do not require FDA approval. There are many such examples on the market.
-- Last week's tabloid story's lack of an understanding of Health Discovery Corporation's pioneering and patented Support Vector Machine technology is revealed in its dismissive language regarding the Company's mobile phone application for skin cancer risk management. The Company is already receiving serious partnership inquiries from respected labs from around the world that actually understand the importance of this technology in melanoma risk assessment. Everyone knows that early detection of melanoma saves lives.
Yes, read that WSJ article.
However, to summarize - the article does refer to the use of a bio-marker to track the progression of a tumor - which will get patented by Hopkins Univ - so, no affiliation with any company at this time (that we can invest).
One of these days they (media) will make the connection of personalized medicine and bio-markers used in simple diagnostic tests such as HDVY's - not there yet. Will be interesting to see how it progresses.
Excellent rebuttal! Point by point.
Thank you for taking the effort to do so.
True. That is why it is critical to do due diligence (as most of the longs here have done) prior to deciding to buy or not to buy - by just looking at facts (easier said than done).
It pays to trust yourself and know the facts. Sadly there are several others outside this board who constantly mislead.
I am still long and will accumulate if it dips into the teens.
This is not a trading stock for me, rather - a long term hold. There are far more liquid large cap equities that I trade.
Well said... much of what you read online is biased.
We have to be careful with filtering facts from hidden agendas.
And that takes a lot of effort - and is very difficult.
Easier to just swallow what is "fed". Much harder to think! It takes a great deal of effort to read "between the lines" and be objective. Very very few sources do that.
Sadly, much of media has decayed to what it is now.
On Wall Street, nothing happens out of luck - most of the trades are very well orchestrated!
Billions to be made - luck is not in the picture for the folks that control the market.
Excellent research Bob...
Looks like it - I do not trust anything from Street.com! They are not objective in their reasoning.
long message... Street.com --- Biotech Stock Mailbag: Health Discovery
http://www.thestreet.com/_yahoo/story/10683805/1/biotech-stock-mailbag-health-discovery.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
BOSTON (TheStreet) -- This week's Biotech Stock Mailbag opens with an email from Edward M. with a question about Health Discovery Corp(HDVY.OB Quote).
"Health Discovery Corp. recently received a bullish write-up by Biomedreports that said certain undisclosed actions would be taken very soon to implement the company's urine-based test for prostate cancer. Did you see this report and if so, what is your position? If Health Discovery Corp.'s urine-based test works it could become the gold standard for prostate cancer and replace PSA tests because those don't work at all and doctors want something else."
Health Discovery (HDC) is working on a urine-based genetic test for prostate cancer, along with partners that include Quest Diagnostics(DGX Quote), Clarient(CLRT Quote) and Abbott Labs(ABT Quote). That much from Biomedreports' recent coverage of the company is true.
Unfortunately, more of what was reported by Biomedreports about HDC contained factual omissions and exaggerations that distort both the timeliness of the company's prostate cancer test as well its near-term commercial potential.
HDC's urine-based test doesn't appear to be close to clinical validation or commercialization, according to checks I made with HDC's partners. And even if a convenient and accurate urine-based gene test for prostate cancer was launched soon, it would not replace the widely used, if flawed, PSA blood test -- certainly not right away, according to cancer experts.
Trading in Health Discovery (HDC) surged on Jan. 29, triggered by a Biomedreports alert to its paying subscribers that morning:
"... speculation centers on news surrounding the company's new gene-based molecular diagnostic test for prostate cancer -- which has successfully completed its phase III double-blind clinical trial and is now ready for commercialization. The new prostate cancer test will be performed at Clarient's clinical laboratory in Aliso Viejo, Calif. HDC will receive 30% royalty on each test performed," the Biomedreports alert stated.
By the close of trading on Jan. 29, HDC's stock price rose 6 cents, or 27%, to 28 cents a share. The intraday high reached 31 cents. More than 12 million shares traded hands, 12 times the average daily trading volume in the stock.
This "news" was more than a year old! HDC announced a tissue-based genetic test for prostate cancer ready for commercialization in the fall of 2008 after the completion of a phase III study earlier that year. This test requires a piece of a patient's prostate obtained through a biopsy, and looks for the presence of four genes that HDC claims signals the presence of aggressive prostate cancer cells.
Clarient, one of HDC's partners, launched this tissue-based prostate cancer test in January 2009 as a so-called "homebrew" or in-house laboratory test, which doesn't require approval from the U.S. Food and Drug Administration.
A year later, however, sales of the HDC-Clarient prostate cancer test are "immaterial," according to Clarient spokesman Matt Clawson.
The HDC prostate cancer test is a "very small part of our business and we don't spend a lot of time talking about it," added Clawson.
On Feb. 1, Biomedreports published a more detailed, follow-up report on HDC available for free on its web site. This story suggested that HDC was about to announce a major development with a urine-based prostate cancer test and quoted an unnamed HDC executive who said the company wouldn't be able to say very much for "at least a few days" because of some "very sensitive non-disclosure agreements that are in place with both existing and potential partners."
"Speculators appear to be betting that HDC's new prostate cancer test is not only about to be commercialized, but that it has a very good chance of replacing the current PSA test for multiple reasons, including the fact that HDC's urine-based prostate cancer test is non invasive (only requiring a urine sample) while the PSA test requires an invasive blood collection procedure," according to Biomedreports.
That report helped push shares of HDC to an intraday high of 38 cents on Feb. 5, again, on larger-than-average volume.
Quest Diagnostics, one of the country's largest laboratory testing companies, confirmed for me that it did license from HDC last year the rights to develop a urine-based aimed at detecting aggressive or clinically significant prostate cancer. Quest is also working with technology from other companies to accomplish the same thing.
Quest spokeswoman Wendy Bost declined to say how close such a test is to reaching the market but she did say that any urine-based test for prostate cancer from Quest would not replace the PSA test.
"Our research and development activities center on developing new techniques, employing urine and tissue specimens, that can complement, not replace, PSA testing. PSA testing plays an important role in the detection of this cancer. This role could be more powerful if the results of other validated biomarkers are available to physicians for assessing, in concert with a PSA result, a patient's likelihood for malignancy prior to biopsy or surgery," said Bost, in an email.
Abbott Labs spokeswoman Adelle Infante, likewise, confirms the company is working with HDC's urine-based prostate cancer screening technology, but "we are still early in the development process," with initial studies only underway, she said. Any test coming out of Abbott's labs will have to first be approved by the FDA before it reaches the market, she added.
Clarient also has rights to develop a urine-based prostate cancer test based on HDC technology, but any such test is "not ready for commercialization," said spokesman Clawson.
HDC won't say much about the timelines for a urine-based prostate cancer-screening test, nor does the company have any clinical data to share on such a test. HDC spokesman Tom Gallagher said the company is restricted by confidentiality agreements with its partners.
Gallagher declined to provide details about any clinical trials specifically investigating the accuracy of a urine-based prostate cancer test that relies on the HDC-discovered genes that allegedly signal aggressive tumors. On several occasions, Gallagher promised to connect me with HDC CEO Stephen Barnhill, but he never followed through.
Researchers working on behalf of HDC did publish a paper in the journal UroToday International last year on the company's tissue-based test, but no details about extending the technology to urine-based screen were included, nor has the FDA reviewed the data.
Other companies and research groups are busy working on developing urine-based tests for prostate cancer. The diagnostics firm Gen-Probe(GPRO Quote) already sells a urine test for prostate cancer in Europe. The company is now running clinical trials in the U.S. with plans to get the test approved here.
A need does exist for a better way to screen patients for prostate cancer because the current PSA test is not specific enough, which means it doesn't do a good job of distinguishing between non-cancerous conditions like an enlarged prostate and serious, aggressive cancers, says Dr. Otis Brawley, medical director of the American Cancer Society.
But any new prostate cancer test that is developed will need to be reviewed and approved by the FDA. Then, it will take years of follow-up data before doctors are comfortable replacing the PSA test completely, Brawley says.
"This is not something that is going to happen overnight," he added.
Meantime, HDC issued Tuesday what has to be the most far-fetched and ridiculous press release I've seen in a long time. The company announced it was completing a mobile phone application that will allow anyone to take a picture of a suspicious mole on their bodies, email the photo to HDC, then immediately receive back a report outlining a risk assessment for melanoma.
Any company that claims to be able to diagnose skin cancer based on an emailed cell phone snapshot is acting completely irresponsibly, even recklessly, because it puts peoples' lives at risk. Hopefully, the FDA learns about this nonsense and orders HDC to cease and desist before someone gets hurt.
By the way, Biomedreports described the mobile phone app for skin cancer as "impressive" and "good news." I'm gobsmacked. Is there anything Biomedreports won't do or say to promote penny biotech stocks?
Upcoming Court dates ... from Yahoo msg board
"The hearing from Dec. 16 was continued until Dec 22 essentially. After a 3 hour hearing yesterday Cobalis has a new lawsuit claim estimation hearing date regarding the YAG debt owed of March 10 and a new plan confirmation hearing date on the feasibility and approval of the Cobalis CH 11 reorganization plan of March 24.
Plan documents will be mailed to creditors and shareholders in late January or early February now.
Cobalis continues to deal with these costly legal issues and move forward to execute their operational, marketing and distribution plans.
These are facts as we know them today. You may share this information as you see fit. PR releases are costly and the legal issues and key dates have been changing quickly of late. Yet Cobalis is committed to keeping loyal investors and the public informed of the material key dates during this reorganization effort".
Check out the post by "dollardaze" posted yesterday evening - his link provides you the info you seek.
Great news - MDFI is gearing towards getting a lot of contracts from the government.
Excellent move MDFI!
True - it caught everybody by surprise - and most wish they could have traded it! Or even capture a small portion of the astronomical gains!
I did not trade that. Too volatile for my type of trading.
Very few trade that ... given that it has finished the run!
So, based on that I suspect that few post on the current VRMLQ board.
It appears that HDVY is trying to aggressively portray itself - regarding today's news about "Best and Brightest" PR'd by the company itself.
Good for the company!
Vermillion Inc: On Track To Launch OVA1T With Quest Diagnostics In March
We wait and watch the response...
Slowly everyone will begin to understand Electronic medical records ...
'Your Medical Records Online: The Promises and the Pitfalls'
Last update: 2/17/2010 3:19:00 PM
LOS ANGELES, Feb 17, 2010 /PRNewswire via COMTEX/ -- Science Matters Program Explores the Consequences of Digitizing Medical Records Presented by the California Science Center
The California Science Center's Science Matters, a speaker's program that explores current science issues in the forefront of public concern, will present "Your Medical Records Online: The Promises and the Pitfalls" February 20, 2010 from 1:00-2:40 p.m. The program is free to the public and will take place in the Loker Conference Center at the California Science Center.
The federal government has set a goal for every American to have an electronic health record by 2014. Who will benefit? Who will pay? And what are the dangers inherent in the digitalization? How can the security of personal data be protected, regulated and monitored? Expert panelists, including Dr. Paul Tang who was recently listed as one of the 100 Most Powerful People in Healthcare and named to the 2009 Most Powerful Physician-Executive list, will explore the technical, societal and ethical dimensions of this urgent issue.
Conan Nolan, NBC4 reporter and co-host of News Conference, will serve as moderator for this panel discussion.
Panelists include: Paul Tang, M.D., M.S. Internist, Vice President, and Chief Medical Information Officer at Palo Alto Medical Foundation, Consulting Associate Professor of Medicine (Biomedical Informatics) at Stanford University; Claire Pomeroy, M.D., M.B.A., Vice Chancellor for Human Health Sciences and Dean of the School of Medicine at UC Davis; Nadereh Pourat, Ph.D., Director of Research Planning, UCLA Center for Health Policy Research, Associate Professor, UCLA School of Public Health; and Steven R. Smith, J.D., M.A., President, Dean and Professor of Law at California Western School of Law, San Diego.
Program attendees will have a chance to hear the debates on this issue and to ask questions of the panelists at the end of the program. All those interested in attending may RSVP at 213-744-2420.
About the California Science Center
The California Science Center's mission is as follows: "We aspire to stimulate curiosity and inspire science learning in everyone by creating fun, memorable experiences, because we value science as an indispensable tool for understanding our world, accessibility and inclusiveness, and enriching people's lives."
General Info: Admission is free; to reserve a seat please RSVP at 213-744-2420.
The California Science Center and IMAX Theater are located in historic Exposition Park just west of the Harbor (110) Freeway at 700 Exposition Park Drive, Los Angeles. Open daily from 10 a.m. to 5 p.m., except on Thanksgiving, Christmas and New Year's Day. General admission is free. For recorded information, including IMAX show times, call 323.SCIENCE (323.724-3623). IMAX ticket prices range from $5.00 to $8.25. For advance ticket purchases, group rates, or to make reservations for any visiting group of 15 or more (required), call 213.744-2019. Parking is available in the guest lot at Figueroa and 39th / Exposition Park Drive at $8 per car, $25 for buses or oversized vehicles. Both the Science Center and IMAX Theater are wheelchair accessible. For further information, please visit our website at .
Media Contact: Kristina Kurasz (213) 744-7446 kkurasz@cscmail.org
SOURCE California Science Center
Yes - steady accumulation going on. Likely by the institutions.
Getting ready to break through the .42 ceiling.
Will it and when ... ? ? ?
Stay tuned
Reminder - Feb 22-24 {next week} - both Norris & Barnhill are speaking at the Personalized medicine conference.
Personalized Medicine Conference
SVM will continue to help this little company penetrate into new industries.
Stay LONG and prosper.
That's interesting Degreed. While HDVY waits for the Prostate test, they are busy working on other revenue streams.
Terrific news - what an innovative way of each person taking charge!
This should be interesting....
One of the many new directions this company will grow!
"To help our customers get state-of-the-art expert medical care for their melanoma and other skin cancers, Health Discovery Corporation intends to create a worldwide network of partners that includes physicians who perform skin biopsies and clinical pathology laboratories that analyze skin biopsies"
Took a decent position in this company. Chart looks great.
Will buy more on dips.
Sure - exciting times ahead for us longs.
Now that we got the millions to start slowly getting pumped into the medical infrastructure system - MDFI and other electronic health record related companies should flourish.
Good to be long and watch this company grow!
Stay LONG and prosper!